Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2022-04-18 Environmental & Social …
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司2021年度社会责任报告
Environmental & Social Information Classification · 100% confidence The document is titled '2021年度社会责任报告 Social Responsibility Report' and contains detailed sections on company governance, environmental management, social responsibility initiatives, and sustainability practices. It references the reporting period as the full year 2021 and includes extensive narrative and data on environmental, social, and governance (ESG) factors. There is no indication that this is an announcement or a brief summary; rather, it is a comprehensive report focused on the company's social responsibility performance. This matches the definition of an Environmental & Social Information (SR) report.
2022-04-18 Chinese
圣湘生物科技股份有限公司独立董事对公司对外担保情况的专项说明
Regulatory Filings Classification · 95% confidence The document is a special statement by independent directors regarding the company's external guarantees for the fiscal year 2021. It references regulatory guidelines from the China Securities Regulatory Commission and confirms no external guarantees were made during the period. The document is short (314 characters) and serves as a formal attestation or certification by the independent directors rather than a full financial report or audit. It does not contain financial statements or detailed analysis but is a regulatory compliance statement. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure without substantive financial data or report content.
2022-04-18 Chinese
圣湘生物科技股份有限公司第一届监事会2022年第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 圣湘生物科技股份有限公司 regarding multiple agenda items including approval of the 2021 annual profit distribution plan, the 2021 annual report and its summary, reappointment of the audit firm for 2022, a special report on the use of raised funds, the 2021 social responsibility report, the Supervisory Board's work report, the 2022 Supervisory Board remuneration plan, and the 2022 first quarter report. The document contains no detailed financial statements or substantive financial data itself but confirms the approval and submission of these reports to the shareholders' meeting. The document length is 2487 characters, which is relatively short and mainly serves as an announcement of resolutions and approvals rather than the full reports themselves. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal announcement of supervisory board meeting resolutions and approvals of various reports, not the reports themselves.
2022-04-18 Chinese
圣湘生物科技股份有限公司关于2021年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2021 annual profit distribution plan of the company 圣湘生物科技股份有限公司. It details the dividend per share, total cash dividends, reasons for the dividend payout ratio being below 30%, and the decision-making process including board and supervisory committee approvals. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related explanations. It is a formal announcement to shareholders about dividend amounts and payment plans, which fits the definition of a Notice of Dividend Amount (DIV). The document length is 3576 characters, which is relatively short and consistent with a dividend announcement rather than a full annual report or interim report. Therefore, the appropriate classification is DIV.
2022-04-18 Chinese
圣湘生物科技股份有限公司2021年度独立董事述职报告
Governance Information Classification · 95% confidence The document is titled as an "Independent Directors' Report for the year 2021" from 圣湘生物科技股份有限公司. It details the independent directors' duties, attendance, independence, oversight on related party transactions, use of raised funds, internal controls, and other governance matters for the fiscal year 2021. It is a detailed report on the independent directors' activities and opinions rather than a general annual report or financial statement. It does not contain financial statements or earnings data but focuses on governance and oversight by independent directors. This type of document is typically classified as a Management Report or a Governance Information report. Given the focus on independent directors' duties and governance oversight, the best fit is Governance Information (CGR). The document length is over 5,000 characters and contains substantive content, so it is not a mere announcement or certification. Therefore, the classification is CGR with high confidence.
2022-04-18 Chinese
圣湘生物科技股份有限公司2021年年度报告全文
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The presence of an audit report with an unqualified opinion is mentioned, and the document is extensive (15,000 characters, part of a 280-page report). It includes comprehensive financial metrics, quarterly data, profit distribution plans, and detailed management commentary. This matches the definition of an Annual Report (10-K) which covers company activity and full financial performance for the year. There is no indication that this is merely an announcement or a certification, and the content is substantive and detailed, not just a summary or presentation. Therefore, the correct classification is Annual Report (10-K). FY 2021
2022-04-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.